To validate the above-mentioned results, we analyzed publicly available breast cancer databases to determine the extent to which target genes downstream of the JAK2–STAT3 and TrkA pathways are enriched in triple-negative and HER2-enriched breast cancers. This evidence concerns the gene NTRK1 and breast cancer.